Anti-LPL Antibody

WB,ELISA

Western blot (1:100) and ELISA (1:200~500) in lipid metabolic research. Lipoprotein lipase (LPL) is the central enzyme in plasma triglyceride hydrolysis and is secreted by macrophages in the subendothelial space. Evidence has been provided that LPL produced by macrophages in the vessel wall exerts proatherogenic effects. The atherogenic effects of LPL have been mainly attributed to its ability to favor lipid accumulation within macrophages present in the atherosclerotic lesion. Recently, it has also been shown that LPL promotes the development of atherosclerosis through facilitation of monocyte adhesion to endothelial cells, stimulation of tumor necrosis factor alpha (TNF ) secretion, and induction of vascular smooth muscle cell proliferation.

Human LPL whole protein

LPL encodes lipoprotein lipase, which is expressed in heart, muscle, and adipose tissue. LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism. [provided by RefSeq, Jul 2008]